JP2022513412A5 - - Google Patents
Info
- Publication number
- JP2022513412A5 JP2022513412A5 JP2021548569A JP2021548569A JP2022513412A5 JP 2022513412 A5 JP2022513412 A5 JP 2022513412A5 JP 2021548569 A JP2021548569 A JP 2021548569A JP 2021548569 A JP2021548569 A JP 2021548569A JP 2022513412 A5 JP2022513412 A5 JP 2022513412A5
- Authority
- JP
- Japan
- Prior art keywords
- csf
- cells
- pharmaceutical composition
- exon
- csf gene
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862753485P | 2018-10-31 | 2018-10-31 | |
| US62/753,485 | 2018-10-31 | ||
| PCT/US2019/059275 WO2020092850A1 (en) | 2018-10-31 | 2019-10-31 | Materials and methods for treating cancer |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022513412A JP2022513412A (ja) | 2022-02-07 |
| JP2022513412A5 true JP2022513412A5 (https=) | 2022-11-04 |
Family
ID=95341689
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021548569A Pending JP2022513412A (ja) | 2018-10-31 | 2019-10-31 | 癌を治療するための物質及び方法 |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US20220040229A1 (https=) |
| EP (1) | EP3873205B1 (https=) |
| JP (1) | JP2022513412A (https=) |
| KR (1) | KR20210105344A (https=) |
| CN (1) | CN113194715B (https=) |
| AU (1) | AU2019374102A1 (https=) |
| BR (1) | BR112021008263A2 (https=) |
| CA (1) | CA3116412A1 (https=) |
| IL (1) | IL282478A (https=) |
| MX (1) | MX2021004993A (https=) |
| SG (1) | SG11202103589XA (https=) |
| WO (1) | WO2020092850A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4314037A4 (en) * | 2018-10-31 | 2025-06-04 | Mayo Foundation For Medical Education And Research | Materials and methods for treating cancer |
| EP3773918A4 (en) | 2019-03-05 | 2022-01-05 | Nkarta, Inc. | CD19 DIRECTED CHIMERIC ANTIGEN RECEPTORS AND THEIR USES IN IMMUNOTHERAPY |
| EP4370676A2 (en) * | 2021-06-18 | 2024-05-22 | Artisan Development Labs, Inc. | Compositions and methods for targeting, editing or modifying human genes |
| WO2023081252A1 (en) * | 2021-11-03 | 2023-05-11 | Mayo Foundation For Medical Education And Research | Methods and materials for improving t cell therapies |
| CN114606237B (zh) * | 2022-05-11 | 2025-10-28 | 上海优替济生生物医药有限公司 | Gm-csf抑制剂及其用途 |
Family Cites Families (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US674A (en) | 1838-04-05 | Draft-box eob steam-engines | ||
| US9017A (en) | 1852-06-15 | Cast-iron cab-wheel | ||
| US7741450B2 (en) * | 2006-02-08 | 2010-06-22 | Morphotek Inc. | Antibodies to GM-CSF |
| US20100055116A1 (en) * | 2006-04-13 | 2010-03-04 | Liou Hsiou-Chi | Methods and Compositions for Targeting c-Rel |
| CN101165070B (zh) * | 2006-10-20 | 2010-12-08 | 余波 | 一系列双重生物活性的融合蛋白及其医疗应用 |
| EP2101780B1 (en) * | 2006-11-21 | 2013-10-09 | Kalobios Pharmaceuticals, Inc. | Methods of treating chronic inflammatory diseases using a gm-csf antagonist |
| TW200918553A (en) * | 2007-09-18 | 2009-05-01 | Amgen Inc | Human GM-CSF antigen binding proteins |
| WO2009134805A2 (en) | 2008-04-28 | 2009-11-05 | Kalobios Pharmaceuticals, Inc. | Antibodies to granulocyte-macrophage colony-stimulating factor |
| US20140127814A1 (en) * | 2010-08-10 | 2014-05-08 | Srinivasan Chandrasegaran | Generation and use of pluripotent stem cells |
| CN103827143A (zh) * | 2011-07-06 | 2014-05-28 | 莫弗系统股份公司 | 抗cd20抗体和抗gm-csf抗体的治疗性组合产品及其用途 |
| HRP20230297T1 (hr) * | 2012-07-13 | 2023-05-12 | The Trustees Of The University Of Pennsylvania | UPRAVLJANJE TOKSIČNOŠĆU ZA ANTI-TUMORSKO DJELOVANJE CAR-a |
| CN113684185A (zh) * | 2013-02-26 | 2021-11-23 | 纪念斯隆-凯特琳癌症中心 | 用于免疫疗法的组合物和方法 |
| US20160186208A1 (en) * | 2013-04-16 | 2016-06-30 | Whitehead Institute For Biomedical Research | Methods of Mutating, Modifying or Modulating Nucleic Acid in a Cell or Nonhuman Mammal |
| WO2015066262A1 (en) * | 2013-11-04 | 2015-05-07 | Trustees Of Dartmouth College | Methods for preventing toxicity of adoptive cell therapy |
| WO2015075195A1 (en) * | 2013-11-22 | 2015-05-28 | Cellectis | Method of engineering chemotherapy drug resistant t-cells for immunotherapy |
| JP6202339B2 (ja) * | 2013-12-19 | 2017-09-27 | 国立研究開発法人国立精神・神経医療研究センター | ＧＭ−ＣＳＦ産生Ｔ細胞制御剤、及びＴｈ１／Ｔｈ２免疫バランス調節剤 |
| WO2015121454A1 (en) * | 2014-02-14 | 2015-08-20 | Cellectis | Cells for immunotherapy engineered for targeting antigen present both on immune cells and pathological cells |
| AU2015244039B2 (en) * | 2014-04-07 | 2021-10-21 | Novartis Ag | Treatment of cancer using anti-CD19 chimeric antigen receptor |
| RU2696312C2 (ru) * | 2014-07-16 | 2019-08-01 | Трансген Са | Онколитический вирус для экспрессии модуляторов иммунологических контрольных точек |
| MX392487B (es) * | 2014-10-20 | 2025-03-21 | Juno Therapeutics Inc | Métodos y composiciones para dosificación en terapia celular adoptiva. |
| WO2016073381A1 (en) * | 2014-11-03 | 2016-05-12 | Cerus Corporation | Compositions and methods for improved car-t cell therapies |
| CN105884828A (zh) * | 2015-02-16 | 2016-08-24 | 上海迪诺医药科技有限公司 | 多环化合物、其药物组合物及应用 |
| WO2017040930A2 (en) * | 2015-09-03 | 2017-03-09 | The Trustees Of The University Of Pennsylvania | Biomarkers predictive of cytokine release syndrome |
| EP3353296B1 (en) * | 2015-09-24 | 2020-11-04 | Editas Medicine, Inc. | Use of exonucleases to improve crispr/cas-mediated genome editing |
| WO2017079400A1 (en) * | 2015-11-04 | 2017-05-11 | The Trustees Of The University Of Pennsylvania | Methods and compositions for gene editing in hematopoietic stem cells |
| US11815514B2 (en) * | 2015-12-04 | 2023-11-14 | Juno Therapeutics, Inc. | Methods and compositions related to toxicity associated with cell therapy |
| CN109069539A (zh) * | 2016-02-18 | 2018-12-21 | 恩立夫克治疗有限责任公司 | 用于癌症治疗的联合免疫疗法和细胞因子控制疗法 |
| CN106399375A (zh) * | 2016-08-31 | 2017-02-15 | 南京凯地生物科技有限公司 | 利用CRISPR/Cas9敲除人PD‑1基因构建靶向CD19CAR‑T细胞的方法 |
| JP2020507339A (ja) * | 2017-02-07 | 2020-03-12 | エムイー セラピューティクス インコーポレーテッド | 抗ｇ−ｃｓｆ抗体及びその使用 |
| CN107271675B (zh) * | 2017-03-24 | 2020-06-02 | 郑猛 | 抗人adrb3单克隆抗体及其在疾病诊断和治疗中的应用 |
| AU2018345751A1 (en) * | 2017-10-02 | 2020-05-07 | Humanigen, Inc. | Methods of treating immunotherapy-related toxicity using a GM-CSF antagonist |
| JP7411578B2 (ja) * | 2018-06-01 | 2024-01-11 | マヨ ファウンデーション フォー メディカル エデュケーション アンド リサーチ | 癌を治療するための物質及び方法 |
-
2019
- 2019-10-31 WO PCT/US2019/059275 patent/WO2020092850A1/en not_active Ceased
- 2019-10-31 CA CA3116412A patent/CA3116412A1/en active Pending
- 2019-10-31 KR KR1020217016530A patent/KR20210105344A/ko not_active Withdrawn
- 2019-10-31 CN CN201980072681.3A patent/CN113194715B/zh not_active Expired - Fee Related
- 2019-10-31 SG SG11202103589XA patent/SG11202103589XA/en unknown
- 2019-10-31 JP JP2021548569A patent/JP2022513412A/ja active Pending
- 2019-10-31 MX MX2021004993A patent/MX2021004993A/es unknown
- 2019-10-31 US US17/290,185 patent/US20220040229A1/en active Pending
- 2019-10-31 BR BR112021008263-8A patent/BR112021008263A2/pt not_active Application Discontinuation
- 2019-10-31 AU AU2019374102A patent/AU2019374102A1/en not_active Abandoned
- 2019-10-31 EP EP19880756.2A patent/EP3873205B1/en active Active
-
2021
- 2021-03-22 US US17/209,160 patent/US20210284714A1/en active Pending
- 2021-04-20 IL IL282478A patent/IL282478A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022513412A5 (https=) | ||
| Hu et al. | Nucleofection with plasmid DNA for CRISPR/Cas9-mediated inactivation of programmed cell death protein 1 in CD133-specific CAR T cells | |
| US20250074965A1 (en) | Anti-ptk7 immune cell cancer therapy | |
| EP3368689B1 (en) | Composition for modulating immune responses by use of immune cell gene signature | |
| US11180730B2 (en) | Compositions and methods for evaluating and modulating immune responses by detecting and targeting GATA3 | |
| Ye et al. | Human macrophage and dendritic cell-specific silencing of high-mobility group protein B1 ameliorates sepsis in a humanized mouse model | |
| JP7411578B2 (ja) | 癌を治療するための物質及び方法 | |
| JP2023096078A (ja) | 自己免疫疾患およびがんを処置するための組成物および方法 | |
| JP7471289B2 (ja) | 抗ｌｉｖ１免疫細胞癌療法 | |
| US20170283807A1 (en) | Compositions and methods for diagnosis and treatment of prostate cancer | |
| US20180010132A1 (en) | Inhibition of prmt5 to treat mtap-deficiency-related diseases | |
| WO2017075451A1 (en) | Compositions and methods for evaluating and modulating immune responses by detecting and targeting pou2af1 | |
| JP2023508740A5 (https=) | ||
| CN109121413A (zh) | 使用靶向核酸纳米载体编程治疗性细胞的组合物和方法 | |
| JP2021525519A5 (https=) | ||
| JP2022517461A5 (https=) | ||
| CN113194715B (zh) | 用于治疗癌症的材料和方法 | |
| JP2022512922A (ja) | キメラ抗原受容体記憶様（ｃａｒｍｌ）ｎｋ細胞ならびにその産生および使用方法 | |
| Erlandsson et al. | IGF1R signalling is a guardian of self-tolerance restricting autoantibody production | |
| CN119384509A (zh) | 多核苷酸 | |
| WO2024059821A2 (en) | Car t cell compositions for treatment of cancer | |
| US11053503B2 (en) | Methods and means of generating IL-17 associated antitumor effector cells by inhibition of NR2F6 inhibition | |
| EP3635098B1 (en) | T-cells modified to overexpress phf19 | |
| Zhang et al. | Constitutive STAT3 Signaling, in Comparison with STAT5, Enhances CAR T-cell Efficacy and Lowers Systemic Toxicity | |
| Niu et al. | Local delivery of IL-15 and anti-PD-L1 nanobody by in vitro-transcribed circILNb elicits superior antitumor immunity in cold tumors |